SCHEMBL3877880

SCHEMBL3877880

CN1CCc2c([nH]c3ccc([N+](=O)[O-])cc23)C1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
GFER P55789 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
BAZ2B Q9UIF8 1/20 0.61
KDM4E B2RXH2 1/20 0.57
SLC6A4 P31645 1/20 0.49
LMNA P02545 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
HTT P42858 1/20 0.49
NCOA1 Q15788 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TRPV1 Q8NER1 2/20 0.48
FAAH O00519 1/20 0.48
HTR6 P50406 2/20 0.48
ALDH1A1 P00352 1/20 0.47
DRD2 P14416 2/20 0.46
DRD1 P21728 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3873162 0.90 KDM4E (0.57) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL13328971 0.90 BAZ2B (0.71) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3877884 0.86 MAPT (0.62) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3874478 0.84 MAPT (0.57) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3887465 0.84 MAPT (0.60) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL3874692 0.79 MAPT (0.56) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL31233605 0.78 MAPT (1.00) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL699222 0.78 MAPT (1.00) MAPTMEN1KMT2AGFERSMN1; SMN2
SCHEMBL1120507 0.78 L3MBTL1 (0.76) MEN1KMT2ASMN1; SMN2BAZ2BKDM4E
SCHEMBL5546886 0.77 MEN1 (0.51) MAPTMEN1KMT2AGFERSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
US-8263609-B2 Tetrahydro-β-carbolin-sulfonamide derivatives as 5-Ht6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2012-09-11 US disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
EP-1919475-B1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS ESTEVE LABOR DR (ES) 2009-03-11 EP disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands LABORATORIES DEL DR. ESTEVE, S.A. (ES) 2008-11-13 US disclosed
EP-1919475-A1 TETRAHYDRO- BETA-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS Laboratorios del Dr. Esteve S.A. (ES) 2008-05-14 EP disclosed
WO-2007028460-A1 TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-15 WO disclosed
WO-2007028460-A1 TETRAHYDRO-β-CARBOLIN-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-03-15 WO disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed
EP-1747779-A1 Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280942-A1 Tetrahydro-Beta-Carbolin-Sulfonamide Derivatives as 5-Ht6 Ligands HTR6, HTR5A, HTR1B MAPT 2845/4885MEN1 2781/4885KMT2A 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.